MACROTEC
LOE ApproachingBLAINJECTIONINJECTABLE
Approved
Feb 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MACROTEC is an injectable biologic approved by Bracco in 1976 with unknown mechanism of action and indication profile. As a legacy biologic therapeutic, it represents a mature product class with established clinical utility. The specific therapeutic area and patient population cannot be determined from available data.
LOE Approaching
Product is nearing loss of exclusivity with moderate competitive pressure (30/100), suggesting brand teams are in defensive/transition mode rather than growth investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MACROTEC offers limited career growth given its LOE-approaching status and zero linked job openings. Opportunities are best suited for professionals interested in legacy product management, defensive marketing, or transition planning into new therapeutic areas.
Brand ManagerField Sales Representative
Worked on MACROTEC at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.